Following OraSure's November 2024 lawsuit accusing NowDx of misappropriating trade secrets, NowDx has countersued OraSure over similar allegations.

The company received conditional approval from New York State for its new systemic lupus erythematosus and rheumatoid arthritis biomarker assays.

Numerous firms reported preliminary revenues along with other business updates on Sunday and Monday ahead of the annual JP Morgan Healthcare Conference.

Last week, readers were most interested in a story about the progress made by test developers toward commercializing rapid tests for sepsis.

The rapid spinning disk-based immunoassay technology will enhance BioMérieux's offering at the point of care, the firm said.